185 related articles for article (PubMed ID: 15056649)
1. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
Jones RN; Moet GJ; Sader HS; Fritsche TR
J Antimicrob Chemother; 2004 May; 53(5):804-7. PubMed ID: 15056649
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2004 May; 49(1):63-5. PubMed ID: 15135503
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
4. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
6. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
7. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
[TBL] [Abstract][Full Text] [Related]
8. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
Fritsche TR; Moet GJ; Jones RN
Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
[TBL] [Abstract][Full Text] [Related]
10. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
12. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
Ross JE; Fritsche TR; Sader HS; Jones RN
Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
[TBL] [Abstract][Full Text] [Related]
13. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
15. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
Sader HS; Streit JM; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
18. Oxazolidinones: activity, mode of action, and mechanism of resistance.
Bozdogan B; Appelbaum PC
Int J Antimicrob Agents; 2004 Feb; 23(2):113-9. PubMed ID: 15013035
[TBL] [Abstract][Full Text] [Related]
19. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Fritsche TR; Sader HS; Cleeland R; Jones RN
Antimicrob Agents Chemother; 2005 Apr; 49(4):1468-76. PubMed ID: 15793128
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]